Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma
NCT05363800Phase 1Active, not recruiting
- Sponsor
- Hengrui
- Start
- Jun 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HRS-3738 in non-Hodgkin lymphoma (NHL) and multiple myeloma (MM), sponsored by Hengrui. Primary endpoints: Maximum Tolerated Dose and Recommended Phase 2 Dose. Started Jun 2022; status: active, not recruiting.
02
Drugs
HRS-3738
03
Conditions
non-Hodgkin lymphoma (NHL)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05363800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05363800.